



## MC and WGs joint meeting

### Action BM1206

21<sup>st</sup>-23<sup>rd</sup> October 2013, Edinburgh  
Hotel Premier Inn Edinburgh City Center (Haymarket)

**COOPERATION STUDIES ON INHERITED SUSCEPTIBILITY  
TO COLORECTAL CANCER**

**Sergi Castellví-Bel**

**COST Domain - Biomedicine and Molecular Biosciences (BMBS)**

 COST is supported  
by the EU Framework Programme

 ESF provides the COST Office  
through a European Commission contract

## Welcome to Edinburgh!

- **PLEASE REMEMBER TO SIGN ATTENDANCE LIST EVERY MEETING DAY**
- ADOPTION OF AGENDA (approval)
- APPROVAL OF KICK-OFF MEETING MINUTES
- UPDATE ON THE ACTION

## Status of the Action

• Participating countries: (proposal) Austria, Czech Republic, Finland, Germany, Italy, Netherlands, Portugal, Spain, Sweden, United Kingdom; (joined after approval) Cyprus, France, FYR Macedonia, Israel, Malta, Romania, Turkey

• France dropped out of the Action (17/09/2013)

• 16 current participating countries

• **ACTION BUDGET STATUS:**  
1<sup>st</sup> year, 1st installment received  
(65%, 55,900€);

inquire top up for 2<sup>nd</sup> installment due to  
increase in number of participating countries

COST Grant budget plan	
Action no. and title: BM1206 - COOPERATION STUDIES ON INHERITED SUSCEPTIBILITY TO COLORECTAL CANCER	
Grant period: 01/05/2013 – 31/05/2014	
Allocated budget: 86.000€	
<b>A. SUMMARY BUDGET</b>	
(1) MEETINGS	€ 60,400
(2) SHORT-TERM SCIENTIFIC MISSIONS	€ 5,500
(3) TRAINING SCHOOLS	€ .....
(4) PUBLICATIONS, DISSEMINATION, OUTREACH	€ 7,980
(5) OERSA	€ 1,000
<b>B. TOTAL SCIENCE EXPENDITURE (sum of (1) to (5))</b>	<b>€ 74,880</b>
<b>C. Financial &amp; Scientific Administration and Coordination (max. of 15% of B.)</b>	<b>€ 11,120</b>
<b>D. TOTAL EXPENDITURE (B+C)</b>	<b>€ 86,000</b>

## Objectives of the network

Main objective: to comprehensively understand the impact of inherited susceptibility in colorectal cancer (CRC) for profiling individual disease risk and performing early screening and treatment monitoring

**NEW MOLECULAR BIOMARKERS WILL BE IMPLEMENTED AND VALIDATED FOR PERSONALIZED CRC MEDICINE**

• Specific objectives:

- ✓ Identification of new CRC susceptibility variants (Obj.1)
- ✓ To pinpoint functional links for CRC susceptibility variants (Obj.2)
- ✓ To link genetic variants to CRC survival and treatment toxicity (Obj.3)
- ✓ To identify genetic variants enriched in CRC subgroups (Obj.4)

## Objectives of the network

- Specific objectives (cont.):

- ✓ To discover new predisposition genes for CRC in families with unknown genetic basis (Obj.5)
- ✓ To detect interactions between CRC susceptibility variants and environment (Obj.6)
- ✓ To develop a high-risk CRC profile of inherited variants by statistical modeling (Obj.7)
- ✓ Articulation and strengthening of cooperative research
- ✓ Gender balance and implication of early-stage researchers
- ✓ Dissemination of results and involvement of stakeholders

## Network management and organisation

- This Action's activities will be organized in four Working Groups:

- ✓ Genetic Association Studies (**WG1**)
- ✓ Functional Genomics (**WG2**)
- ✓ Next Generation Sequencing (**WG3**)
- ✓ Statistical Modeling (WG4)

- Networking by regular meetings, e-mailing and video conferences. Annual work, budget and dissemination plans

- MC/WG meetings (2 per year) and Core Group meetings (if necessary), invited external experts

- Workshops/conference (1 per year): in conjunction with a MC meeting or a scientific-related event, involvement of early-stage researchers

- Short Term Scientific Missions (STSMs): particularly for young scientists

- Training schools: Intensive training on a new and emerging subject relevant to the Action's objectives

## Distribution of Action's tasks

### Management committee

Grant Holder: IDIBAPS, ES; [www.idibaps.org](http://www.idibaps.org)

Chair of the Action: Sergi Castellví-Bel, ES

Vice-chair of the Action: Annika Lindblom, SE

### Working Group chairs

- Genetic Association Studies (WG1): Ian Tomlinson, UK (chair), Dina Ruano, NL (vice-chair)

- Functional Genomics (WG2): José Luis Gómez-Skarmeta, ES (chair), Richard Houlston, UK (vice-chair)

- Next Generation Sequencing (WG3): Tom van Wezel, NL (chair), Claire Palles (vice-chair)

- Statistical Modeling (WG4): Albert Tenesa, UK (chair), Ceres Fernández-Rozadilla, UK (vice-chair)

Financial rapporteurs: Clara Ruiz-Ponte, ES and Jochen Hampe, DE

STSMs committee: Kari Hemminki, DE (chair), Andrea Gsur, AT, Lauri Aaltonen, FI

Publications committee: Ian Tomlinson, UK, Vanessa Petroni, MT,

Web site committee: Sergi Castellví-Bel, ES and Pavel Vodicka, CZ

## Short Term Scientific Missions (STSMs)

- The aim of a STSM is to contribute to the scientific objectives of a COST Action
- These Missions (Exchange Visits) are aimed at strengthening the existing networks by allowing scientists to go to an institution or laboratory **in another COST Country** to foster collaboration, to learn a new technique or to take measurements using instruments and/or methods not available in their own institution/laboratory. They are particularly intended for young scientists
- This Action will open very soon a first call for STSMs. **This first year there will be 4 STSMs available**
- Standard duration: minimum 5 days, maximum 90 days
- Extended duration for Early Stage Researchers (ESR, postdoc up to 8 years after PhD): minimum 91 days, maximum 180 days
- Please refer to COST Vademecum for more detailed information and apply through <https://e-services.cost.eu/stsm>
- STSM Committee: Kari Hemminki (chair), Andrea Gsur, Lauri Aaltonen

## Gender balance and early-stage researchers

- Gender balance always respected in this Action's activities
- Increase involvement of female and early-stage researchers by inviting them to actively participate in this Action
- MC involves 7/17 females (**41%**) and 10/17 young researchers (**59%**) to ensure commitment
- 23/56 females (**41%**) and 32/56 young researchers (**57%**) in this meeting
- Balance training activities and STSMs among genders
- STSMs particularly for young researchers
- Seeking the participation of early-stage researchers will ensure the continuation of this Action's activities beyond the grant period


## Working groups (scientific strategy)

- This Action's activities will be organized in four Working Groups:
  - ✓ Genetic Association Studies (WG1) will comprise all activities related to the identification of new CRC genetic susceptibility variants and correlation of known and newly identified CRC genetic susceptibility variants with CRC survival and treatment response, as well as with CRC subtypes.
  - ✓ Functional Genomics (WG2) will cover research undertaken by participants regarding fine mapping and functional studies for known and newly identified CRC genetic susceptibility variants.
  - ✓ Next Generation Sequencing (WG3) will include all activities related to the identification of new predisposition CRC genes by next generation sequencing.
  - ✓ Statistical Modeling (WG4) will consist of research tasks involved in statistical analyses of gene-gene (epistasis and hereditary CRC modifiers) and gene-environment interactions for CRC genetic susceptibility variants, with a final objective of developing a high-risk profile for CRC to be used as a molecular tool for personalized CRC medicine.

## Dissemination planning

- Initial brochure:
  - ✓ Designed ; 2,000 copies printed
  - ✓ 50 copies handed to each group during this meeting
  - ✓ Aimed to be distributed actively to potential new participants
- Website:
  - ✓ Designed and active
  - ✓ [www.euolongene.eu](http://www.euolongene.eu)
  - ✓ Check that your data is correct; send photo if not available
  - ✓ Contribute with useful material (publications, EU grant info)
- Publications:
  - ✓ Acknowledge COST Action BM1206 in your publications
  - ✓ *"This publication is supported by COST Action BM1206"*

## COST countries



- 28 EU members: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, United Kingdom
- EFTA countries: Iceland, Norway, Switzerland
- EU candidates: fYR Macedonia, Turkey
- EU potential candidates: Bosnia and Herzegovina, Serbia
- Cooperating State: Israel


**36 COUNTRIES**

## Non-COST application to this Action

- Non-COST countries: all the other
- On the basis of mutual benefit. Cannot participate in MC or be reimbursed
- Dr Luis CARVAJAL-CARMONA  
Genome Center & Department of Biochemistry and Molecular Medicine  
School of Medicine  
University of California, Davis (UC Davis), **USA**  
(as stated originally in full proposal)
- Other applications from the CHIBCHA group? Mexico, Uruguay, Brazil

## Location and date of next meeting

- Next MC&WG joint meeting: Barcelona, 12/03/2014
- Translational Genomics in Biomedicine workshop: 13-14/03/2014



**TRANSLATIONAL  
GENOMICS  
IN BIOMEDICINE**

**WORKSHOP  
13-14 March 2014  
IDIBAPS,  
Barcelona**

**Organizers**  
Sergi Castellví-Bel (IDIBAPS, Spain)  
Cristina Fàstet (IDIBAPS, Spain)  
Mercedes Gironella (CIBERERHD, Spain)  
Thomas Reid (National Cancer Institute, USA)  
Lluís Hernández (IDIBAPS, Spain)  
Sílvia Beà (IDIBAPS, Spain)

**Speakers**  
Thomas Reid (National Cancer Institute, USA)  
Sílvia Beà (IDIBAPS, Spain)  
Ramesh Berukhim (Dana-Farber Cancer Institute, USA)  
Tine Nielsen (The Novo Nordisk Foundation Center for Basic Metabolic Research, Denmark)  
Patricia Lepape (MICALIS-INRA, France)  
Xin W. Wang (National Cancer Institute, USA)  
Munesh Tewari (Fred Hutchinson Cancer Research Center, USA)  
Anne-Lise Berresen-Dale (Oslo University Hospital, Norway)  
Jonel Trebbick (University of Bonn, Germany)  
Alexandra Martins (University of Rouen, France)  
Stephan Beck (University College London, UK)  
Peter Jones (USC Norris Comprehensive Cancer Center, USA)  
Antònia Ribes (Hospital Clínic de Barcelona, Spain)  
Richard Houlston (Institute of Cancer Research, UK)  
Xavier Estivill (Centre de Regulació Genòmica, Spain)

**Contact us:**  
To contact the scientific committee  
please write to [sbea@clinicub.es](mailto:sbea@clinicub.es)  
For questions about logistics please contact  
[genal.Meeting@marcs.csic.cat](mailto:genal.Meeting@marcs.csic.cat) or [delmarcs@marcs.csic.cat](mailto:delmarcs@marcs.csic.cat)

**Partners:**  
AFFYMETRIX, AX, ACR, Universitat de Catalunya, Generalitat de Catalunya, ciberer, IDIBAPS, IZASA, Fibrosis, CLÍNIC UB, life, cost, qgenomics, CSIC, Institut d'Investigacions Biomèdiques August Pi i Sunyer, Universitat de Barcelona



## Location and date of next meeting

- Next MC&WG joint meeting: Barcelona, 12/03/2014
- Translational Genomics in Biomedicine workshop: 13-14/03/2014

**DEADLINE FOR REGISTRATION AND ABSTRACT: 15/12/2013**

**Be aware that registration fees cannot be covered by COST (150€ students/250€ senior)**

- Candidate locations for 2<sup>nd</sup> year meetings?
- Any idea for a training school for 2<sup>nd</sup> year? Next-generation sequencing analysis training school?

## COST travel reimbursement 101

- Pay in advance – be reimbursed after the meeting rule
- Pay attention to rules in COST Vademecum (no excessive expense, economy class, flat rate for accommodation and meals, no taxis)
- Use e-COST
- Remember to attach flying ticket/e-ticket showing name, price and itinerary
- Send signed paper copy of the generated Travel Reimbursement Request (TRR) to:  
Dr Juan Manuel ABOLAFIA MOYA  
Consorci Institut D'Investigacions Biomediques August Pi i Sunyer  
Rossello 149  
08036 Barcelona, Spain
- **Deadline to receive TRR: 23/11/2013 (those received will be paid)**



19



**MC and WGs joint meeting**  
**Action BM1206**

21<sup>st</sup>-23<sup>rd</sup> October 2013, Edinburgh  
Hotel Premier Inn Edinburgh City Center (Haymarket)

**COOPERATION STUDIES ON INHERITED SUSCEPTIBILITY  
TO COLORECTAL CANCER**

**Sergi Castellví-Bel**

**COST Domain - Biomedicine and Molecular Biosciences (BMBS)**

## Welcome to Edinburgh!

- **PLEASE REMEMBER TO SIGN ATTENDANCE LIST EVERY MEETING DAY**
- FOLLOW-UP OF COST MoU OBJECTIVES FOR THE FIRST YEAR

## COST MoU objectives for the 1<sup>st</sup> year

- IDENTIFICATION OF NEW CRC SUSCEPTIBILITY VARIANTS
- GENETIC VARIANTS INVOLVED IN CRC SURVIVAL AND TREATMENT TOXICITY
- GENETIC VARIANTS ENRICHED IN CRC SUBGROUPS
- NEW PREDISPOSITION GENES FOR CRC IN FAMILIES WITH UNKNOWN GENETIC BASIS
- ✓ 2 MC/WG joint meetings (Edinburgh and Barcelona)
- ✓ Translational Genomics in Biomedicine workshop (Barcelona)
- STSMs: 4 available for 1<sup>st</sup> year
- ✓ Dissemination: brochure, website (and publications)
- ✓ Financial administration/coordination: IDIBAPS